Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis. Arthritis Rheum. 2013;65(11):2737-2747.
[2]
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339.
[3]
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699.
[4]
Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-567.
[5]
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
[6]
Distler O, Cozzani E, Kowal-Bielecka O, et al. 2023 EULAR recommendations for the management of systemic sclerosis. Ann Rheum Dis. 2023;82(9):1153-1169.
[7]
Hoffmann-Vold AM, Allanore Y, Bruni C, et al. Progressive interstitial lung disease in patients with systemic sclerosis. Lancet Respir Med. 2020;8(7):658-670.
[8]
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2016;374(26):2522-2533.
[9]
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis. Ann Rheum Dis. 2007;66(7):940-944.
[10]
Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. 15th ed. Lippincott Williams & Wilkins; 2005:1691-1720.